Latest news: Grant of share options and Directors’ dealings

Modern scientific drug discovery

Modern science has shown that medicines work by affecting networks in our cells. These networks carry out all the biological processes in our bodies, some of which are changed when we are ill. The networks are formed by many interacting proteins. Medicines work by affecting several key proteins in the particular network that carries out the disease process.

e-Therapeutics finds new medicines for diseases that are still poorly treated. Our approach explicitly addresses the robustness and complexity of biological networks, and is designed to deliver new medicines efficiently for diseases in which there is significant unmet need.

Well funded

e-Therapeutics listed on the London Stock Exchange’s AIM market in 2007. Since its flotation, the Company has received strong support from institutional investors, having raised more than $90 million in this period. The Company is well resourced to discover and develop multiple drug assets for out-licence at various clinical and pre-clinical stages.

Our Clinical Assets

We currently have two candidate medicines that have undergone clinical trials. ETS2101 is an anti-cancer candidate in a phase Ib study that will shortly be completed, and ETS6103 is an antidepressant candidate that has completed a phase IIb study.